Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Anti-integrin antibodies
7 evidence topics · 6 sources
Recommendations for vedolizumab: ACG 2025 guideline
Pivotal trial efficacy of vedolizumab: ACG 2025 guideline
VARSITY head-to-head trial and comparative safety: AGA 2024 living guideline
“The only head-to-head trial was the VARSITY trial where 769 patients with moderate-to-severe UC were randomized to receive either vedolizumab (n=383) or adalimumab (n=386)38. At week 52, a higher rate of clinical remission was observed in the vedolizumab treated patients (31.3%) compared to adalimumab (22.5%). Corticosteroid-free remission rates, however, were higher with adalimumab (21.8%) compared to vedolizumab (12.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This trial noted no difference between the two agents in maintaining clinical remission (20.3% vs 16.0%) in this subpopulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In observational studies, vedolizumab was associated with a lower risk of serious infections compared with TNF antagonists in patients with UC69, 70; there was paucity of evidence for comparative safety of other agents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy of vedolizumab by prior biologic exposure: AGA 2024 network meta-analysis
“Intriguingly, the difference in relative efficacy of a drug in biologic-exposed vs. biologic-naïve patients was significantly greater for some drugs, most notably for vedolizumab and ozanimod in our analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote